DPI developer Iconovo has announced that the Japanese Patent Office has granted the company a patent covering its ICOres dry powder inhaler. According to Iconovo, Sweden and European patents related to ICOres have already been issued.
In March 2019, Iconovo announced that CBC Corporation was taking over development responsibilities from Amneal Pharmaceuticals for a generic version of Symbicort that is based on the ICOres inhaler. In July 2019, the company said that a PK study showed that ICOres delivered budesonide/formoterol as expected when compared to Symbicort Turbuhaler.
Iconovo CEO Orest Lastow commented, “A granted patent is the key to this huge and important market. This will be an advantage to our customers when launching ICOres products in Japan.”
The company has also recently announced an investment into development of a device platform for generic versions of Ellipta products and a collaboration with CrystecPharma.
Read the Iconovo press release.
